Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Official Title

A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma


Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer. Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth and/or spreading of cancer.

Trial Description

Primary Outcome:

  • Phase II: Progression free survival measured as time from randomization to first observation of objective disease relapse or progression
  • Phase III: Overall Survival defined as time from randomization to the date of death from any cause
Secondary Outcome:
  • Number and severity of adverse events
  • Overall Survival
  • Quality of Life using EORTC QLQ-C30
  • Objective Response rate compared using Fisher's exact test
The purpose of this study is to find out what effects a new drug, pembrolizumab has on this type of cancer and if it can offer better results than standard pemetrexed and platinum-based chemotherapy alone. This study will also look at side effects and how the treatments impact quality of life

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society